[Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].
M S LebedkinaDarya S FominaZinaida Yu MutovinaU A MаrkinaP O BogomolovVladimir P ChulanovMar'yana A LysenkoEkaterina AlexeevaPublished in: Terapevticheskii arkhiv (2023)
An analysis of the results of a non-interventional observational study summarized in this article showed the high efficacy and safety of virus-neutralizing MAB combination (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with of risk factors for severe COVID-19 in real word settings.